Global Bacillus Calmette-Guerin (BCG) Vaccine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Bacillus Calmette-Guerin (BCG) Vaccine Market Size

• The global Bacillus Calmette-Guerin (BCG) vaccine market size was valued at USD 61.84 billion in 2024 and is expected to reach USD 92.06 billion by 2032, at a CAGR of 5.10% during the forecast period
• The market growth is primarily driven by the ongoing global efforts to control tuberculosis (TB), particularly in high-burden countries, along with increased immunization programs supported by government and international agencies
• In addition, the resurgence of interest in BCG vaccines for non-specific immune benefits—such as protection against other infections and potential uses in bladder cancer treatment—is contributing to broader market demand. These expanding applications and renewed global health focus are expected to propel steady market growth

Bacillus Calmette-Guerin (BCG) Vaccine Market Analysis

• The BCG vaccine, primarily used for tuberculosis (TB) prevention and certain bladder cancer treatments, remains a cornerstone of immunization programs in developing countries and select clinical applications in developed regions due to its immunotherapeutic and preventive benefits
• Rising global TB prevalence, intensified public health campaigns, and increasing awareness of neonatal immunization have significantly elevated demand for BCG vaccines, particularly in Asia, Africa, and Latin America where TB remains endemic
• Asia-Pacific dominated the BCG vaccine market with the largest revenue share of 49.1% in 2024, fueled by national immunization mandates, high birth rates, and extensive vaccine distribution infrastructure, with India and China representing major consumption hubs supported by public-private healthcare collaborations
• The Middle East & Africa is projected to be the fastest growing region during the forecast period, driven by expanding healthcare access, increased government focus on TB eradication, and international funding support.
• Tuberculosis segment dominated the Bacillus Calmette-Guerin (BCG) vaccine market with a market share of 72.9% in 2024, driven by its widespread inclusion in national immunization programs and critical role in preventing severe TB forms in children

Report Scope and Bacillus Calmette-Guerin (BCG) Vaccine Market Segmentation    

Bacillus Calmette-Guerin (BCG) Vaccine Market Trends

“Expanding Applications Beyond Tuberculosis”

• A notable and expanding trend in the global Bacillus Calmette-Guerin (BCG) vaccine market is its emerging use beyond tuberculosis (TB) prevention, particularly in oncology and immunotherapy. The vaccine’s immunomodulatory properties are increasingly being explored in the treatment of bladder cancer and as a potential therapy for autoimmune diseases and other infections
• For instance, intravesical BCG remains the standard of care for non-muscle invasive bladder cancer (NMIBC), with ongoing clinical trials investigating its efficacy in reducing recurrence and progression
• Moreover, studies are underway evaluating BCG's role in reducing the severity of COVID-19 and other respiratory infections by enhancing innate immunity. These novel uses are contributing to renewed interest and investment in BCG research
• Pharmaceutical companies are responding by enhancing production capabilities and developing optimized BCG formulations for therapeutic use. For example, companies such as Merck and Serum Institute of India are expanding their manufacturing and research pipelines to meet increasing global demand
• This trend of diversification and therapeutic expansion is reshaping the market outlook for BCG vaccines, establishing them as multifunctional biologics beyond their traditional public health role in TB control

Bacillus Calmette-Guerin (BCG) Vaccine Market Dynamics

Driver

“Strong Global Immunization Policies and TB Eradication Initiatives”

• The BCG vaccine market is primarily driven by global TB elimination efforts, especially in high-burden countries such as India, Indonesia, and South Africa, where neonatal BCG vaccination is mandatory under national programs
• International support from WHO, GAVI, and UNICEF ensures large-scale procurement; for instance, GAVI has facilitated BCG distribution in over 70 low-income countries
• Awareness campaigns and healthcare outreach programs have expanded vaccine accessibility in rural and underserved regions, boosting immunization rates
• In countries with high birth rates, such as Nigeria and Pakistan, the growing infant population is contributing to a continuous rise in BCG vaccine demand
• Clinical research is increasingly validating BCG’s non-specific benefits for instance, a 2023 study published in Cell Reports Medicine showed potential in reducing the severity of COVID-19 and other respiratory infections
• Manufacturers such as Serum Institute of India and AJ Vaccines have announced facility expansions to meet rising global BCG demand, particularly in Asia and Africa

Restraint/Challenge

“Supply Limitations and Regulatory Hurdles”

• Production disruptions have caused periodic global shortages; for example, in 2012 and again in 2019, temporary shutdowns at major manufacturers such as Sanofi Pasteur led to vaccine stockouts in multiple countries
• BCG requires stringent cold chain storage (2–8°C), making last-mile delivery difficult in rural areas lacking stable electricity or refrigeration
• Dependence on a few global suppliers—such as Serum Institute, Japan BCG Lab, and Merck—creates a fragile supply chain susceptible to bottlenecks
• Regulatory differences—e.g., differing strain approvals (Moreau, Tokyo, Danish)—between the EU, U.S., and developing markets slow down cross-border vaccine deployment
• While BCG shows promise in oncology and immunotherapy, lack of widespread clinical adoption and regulatory approval limits its therapeutic market potential
• Despite increasing demand, BCG remains a low-profit vaccine, which deters private sector investment in R&D or infrastructure upgrades—illustrated by Merck’s limited expansion despite its pivotal role in bladder cancer BCG

Bacillus Calmette-Guerin (BCG) Vaccine Market Scope

The market is segmented on the basis of disease, population type, drug type, end-users, and distribution channel.

• By Disease

On the basis of disease, the Bacillus Calmette-Guerin (BCG) vaccine market is segmented into tuberculosis, cancer, and others. The tuberculosis segment dominated the market with the largest market revenue share of 72.9% in 2024, driven by its widespread use in neonatal immunization programs across TB-endemic countries. The inclusion of BCG in government-mandated immunization schedules, particularly in developing nations, continues to sustain high demand. BCG’s role in preventing severe pediatric TB forms such as miliary and meningeal TB further reinforces its dominance.

The cancer segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by its established application in treating non-muscle invasive bladder cancer (NMIBC). Increased awareness of intravesical BCG therapy and ongoing research into its broader immunotherapeutic potential are expanding its clinical use.

• By Population Type

On the basis of population type, the Bacillus Calmette-Guerin (BCG) vaccine market is segmented into children, healthcare workers, and others. The children segment dominated the market with the largest revenue share of 67.8% in 2024, driven by widespread neonatal immunization efforts and high birth rates in countries such as India, Nigeria, and Indonesia. National vaccination programs emphasize BCG as an essential early-life intervention against tuberculosis, contributing to consistent global uptake.

The healthcare workers segment is anticipated to witness the fastest growth rate from 2025 to 2032, due to occupational health guidelines promoting BCG vaccination for frontline medical staff, especially in TB-exposed environments. Hospitals and public health agencies are increasingly adopting BCG as a preventive strategy for high-risk workers.

• By Drug Type

On the basis of drug type, the Bacillus Calmette-Guerin (BCG) vaccine market is segmented into immune BCG and therapy BCG. The immune BCG segment held the largest market share of 60.2% in 2024, primarily due to its extensive use in global tuberculosis immunization programs. The segment benefits from stable demand in pediatric vaccinations and high-volume public procurement. Its cost-effectiveness and compatibility with WHO-prequalified supply channels further support its dominance.

The therapy BCG segment is projected to experience robust growth from 2025 to 2032, driven by increasing adoption in bladder cancer treatment. Urology clinics and cancer centers worldwide are relying on BCG as a standard immunotherapy, particularly for early-stage bladder cancer patients.

• By End User

On the basis of end-users, the Bacillus Calmette-Guerin (BCG) vaccine market is segmented into hospitals, specialty clinics, home healthcare, and others. The hospitals segment accounted for the largest market share of 51.6% in 2024, owing to their central role in administering both preventive and therapeutic BCG. Hospitals provide regulated environments for immunization and oncology treatments, enabling large-scale administration under expert supervision.

The specialty clinics segment is expected to register the fastest growth over the forecast period, supported by rising demand for outpatient oncology services and increased cancer diagnosis rates. Urology-focused clinics are particularly significant users of therapeutic BCG for NMIBC patients..

• By Distribution Channel

On the basis of distribution channel, the Bacillus Calmette-Guerin (BCG) vaccine market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. The direct tender segment dominated the market with a revenue share of 49.7% in 2024, attributed to large-scale procurement by government bodies and global health organizations such as UNICEF and GAVI. Direct tendering ensures reliable access in public healthcare systems and supports the delivery of free or subsidized vaccinations in low- and middle-income countries.

The online pharmacy segment is projected to grow at the fastest CAGR from 2025 to 2032, driven by the growing digitalization of healthcare and increased consumer preference for convenient, home-based vaccine access—especially for therapeutic applications in urban areas.

Bacillus Calmette-Guerin (BCG) Vaccine Market Regional Analysis

• Asia-Pacific dominated the Bacillus Calmette-Guerin (BCG) vaccine market with the largest revenue share of 49.1% in 2024, fueled by national immunization mandates, high birth rates, and extensive vaccine distribution infrastructure, with India and China representing major consumption hubs supported by public-private healthcare collaborations
• Countries such as India, China, and Indonesia lead in BCG administration due to national vaccination mandates and robust public health infrastructure supporting widespread newborn immunization
• The region’s dominance is further bolstered by local manufacturing capabilities, favorable public health funding, and the presence of major vaccine producers, ensuring steady supply and cost-effective access for both preventive and therapeutic use

India Bacillus Calmette-Guerin (BCG) Vaccine Market Insight

The India Bacillus Calmette-Guerin (BCG) vaccine market accounted for the largest market revenue share in Asia Pacific in 2024, driven by its large birth cohort, high TB burden, and robust national immunization program. The Universal Immunization Programme mandates BCG vaccination at birth, and initiatives such as the National Tuberculosis Elimination Program ensure widespread access. Strong domestic manufacturing capacity, led by Serum Institute of India, supports both local demand and global export needs.

China Bacillus Calmette-Guerin (BCG) Vaccine Market Insight

The China Bacillus Calmette-Guerin (BCG) vaccine market is experiencing steady growth during the forecast period, supported by comprehensive vaccination policies and government-driven TB control strategies. Neonatal BCG vaccination is routinely administered through the National Immunization Program, while improvements in healthcare infrastructure continue to expand vaccine coverage in rural and underserved regions. China's strong pharmaceutical manufacturing base ensures stable supply across both domestic and regional markets

Indonesia Bacillus Calmette-Guerin (BCG) Vaccine Market Insight

The Indonesia Bacillus Calmette-Guerin (BCG) vaccine market is projected to grow consistently during the forecast period, fueled by the country's high TB incidence and extensive government vaccination programs. BCG is a key component of the Expanded Program on Immunization (EPI), with support from international agencies ensuring equitable vaccine access across its diverse geography. Ongoing healthcare reforms and rising public health awareness are expected to further enhance market penetration

Middle East and Africa Bacillus Calmette-Guerin (BCG) Vaccine Market Insight

The Middle East and Africa (MEA) Bacillus Calmette-Guerin (BCG) vaccine market is witnessing consistent growth, primarily driven by a high tuberculosis burden, growing birth rates, and increased government focus on immunization coverage. Countries such as South Africa, Nigeria, Egypt, Saudi Arabia, and the UAE are key contributors to regional demand, with South Africa leading due to its dual TB and HIV burden. Nigeria stands out as the fastest-growing market, supported by international funding and aggressive rural immunization outreach. Saudi Arabia and the UAE maintain steady vaccine demand through mandatory neonatal vaccination policies and advanced healthcare systems. Efforts by global organizations such as GAVI, WHO, and UNICEF continue to strengthen vaccine accessibility across underserved areas, while improved cold chain infrastructure and public-private healthcare partnerships are enhancing distribution.

South Africa Bacillus Calmette-Guerin (BCG) Vaccine Market Insight

The South Africa Bacillus Calmette-Guerin (BCG) vaccine market captured a major share in the MEA region in 2024, largely driven by the country’s high incidence of tuberculosis and one of the highest TB and HIV co-infection rates globally. BCG vaccination is a mandatory component of the national Expanded Programme on Immunization (EPI), administered at birth in all public and private healthcare facilities. The government, in collaboration with global health organizations such as WHO and the Global Fund, is actively strengthening TB prevention strategies through widespread BCG coverage. Ongoing investments in healthcare infrastructure, improved vaccine cold chain systems, and mobile immunization units are enhancing access in remote and underserved rural areas  

Nigeria Bacillus Calmette-Guerin (BCG) Vaccine Market Insight

The Nigeria Bacillus Calmette-Guerin (BCG) vaccine market is poised for robust growth during the forecast period, supported by the country’s high birth rate—the largest in Africa—and a consistently high TB burden. BCG vaccination is a key part of Nigeria’s National Program on Immunization (NPI), delivered at birth and supported extensively through global health partnerships with GAVI, UNICEF, and WHO. These organizations help subsidize vaccine procurement, improve cold chain logistics, and expand access to vaccines in remote communities. The Nigerian government is also actively working to strengthen primary healthcare services and deploy outreach programs, especially in rural and hard-to-reach areas where TB prevalence is highest.

Bacillus Calmette-Guerin (BCG) Vaccine Market Share

The Bacillus Calmette-Guerin (BCG) Vaccine industry is primarily led by well-established companies, including:

• Serum Institute of India Pvt. Ltd. (India)
• Japan BCG Laboratory (Japan)
• Statens Serum Institut (Denmark)
• Merck & Co., Inc. (United States)
• Bio Farma (Indonesia)
• Sanofi (France)
• InterVax Ltd. (Canada)
• GSBPL (India)
• China National Pharmaceutical Group Co Ltd. (China)
• Microgen JSC (Russia)
• AJ Vaccines A/S (Denmark)
• Bul Bio-NCIPD Ltd. (Bulgaria)
• BCG Vaccine Laboratory (India)
• Taj Pharmaceuticals Ltd. (India)
• Biofabri S.L. (Spain)
• Indian Immunologicals Ltd. (India)
• Tianjin Ringpu Bio-Pharmacy Co., Ltd. (China)
• IDT Biologika GmbH (Germany)
• Haffkine Bio-Pharmaceutical Corporation Ltd. (India)

What are the Recent Developments in Global Bacillus Calmette-Guerin (BCG) Vaccine Market?

• In March 2024, Serum Institute of India, one of the world’s largest vaccine manufacturers, announced the expansion of its BCG production facility to meet growing global demand, particularly from low- and middle-income countries. This move is aimed at enhancing vaccine availability in TB-endemic regions and reinforcing India’s leadership in global BCG supply through scaled manufacturing and affordable pricing models
• In February 2024, Japan BCG Laboratory entered into a partnership with the Bill & Melinda Gates Foundation to improve access to BCG vaccines in underserved regions of Africa and Southeast Asia. This initiative focuses on increasing vaccine coverage through targeted delivery programs and supports research into next-generation BCG formulations for broader therapeutic use
• In November 2023, the World Health Organization (WHO) updated its BCG immunization guidelines, emphasizing the importance of neonatal BCG administration in countries with high TB prevalence. The revision aims to increase early-life immunization rates and reduce pediatric TB mortality, prompting governments to strengthen their national vaccination frameworks
• In October 2023, Bio Farma (Indonesia) announced the successful completion of a large-scale Phase III clinical trial evaluating the extended therapeutic use of BCG for non-muscle invasive bladder cancer (NMIBC). This advancement marks a potential expansion of BCG beyond traditional TB prevention, with the company seeking regional regulatory approvals for cancer applications
• In August 2023, UNICEF launched a regional procurement collaboration in West Africa to ensure uninterrupted BCG vaccine supply chains amid rising birth rates and TB incidence. The initiative includes capacity building for local immunization officers, improved cold chain management, and integrated vaccine distribution in rural and high-risk communities

SKU-59291